

Predicting the CD4 slope in patients starting cART after 1 January 1999

JD Lundgren¹, J Gatell², JR Bogner³, K Lacombe⁴, M Murphy⁵, A Wiercinska-Drapalo⁶, P Reiss⁷, A Lazzarin⁸, AN Phillips⁹, A Mocroft⁹
for the EuroSIDA study group

¹Copenhagen HIV Program, University of Copenhagen, Faculty of Health Sciences, Denmark; ²Hospital Clinic i Provincial, Barcelona, Spain; ³Medizinische Poliklinik, Munich, Germany; ⁴Hospital Saint-Antoine, Paris, France; ⁵Medical College of Saint Bartholomew's Hospital, London, UK; ⁶Medical University, Bialystok, Poland; ⁷Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam, The Netherlands; ⁸Ospedale San Raffaele, Milan, Italy; ⁹Royal Free and University College Medical School, London, UK;

INTRODUCTION

Previous research has demonstrated that CD4 slope is a useful prognostic marker for clinical disease progression in patients starting cART (1).

AIMS

To determine predictors of CD4 slopes in patients starting cART after 1 January 1999.

PATIENTS

EuroSIDA patients satisfying the following criterion were included

- started cART after 1/1/99

- CD4 and VL measured in the 6 months prior to starting cART

cART was defined as treatment with exactly 2 nucleosides/nucleotides plus exactly 1 PI, RTV-boosted-PI, NNRTI or abacavir. Triple class failure (TCF) was defined as previously within EuroSIDA and according to the PLATO definition (2).

METHODS

CD4 slopes were calculated for each successive 3 CD4s and changes in viral load over the same time determined using the viral load closest to the first and third CD4 count used to calculate the slope. Generalised-estimating-equations were used to investigate factors associated with CD4 slope.

RESULTS

1956 patients were included in analyses (Table 1). 21279 CD4 slopes were included in analyses, with a median of 10 per patient (IQR 6-17). The median time covered by the 3 CD4 counts used to derive the slopes was 6 months (IQR 5-8 months).

Figure 1 shows the *unadjusted* annual CD4 slope according to viral load change over the same time period. Figure 2 shows the *unadjusted* CD4 slope according to treatment regimen in use at the first CD4 used to calculate each slope.

Table 2 shows the multivariate factors associated with annual change in CD4 slope:

- periods spent on no antiretrovirals had, on average, a 170/mm³ per year lower increase in CD4 counts compared to periods spent treated with a boosted PI regimen
 - antiretroviral naïve patients had a 22/mm³ per year higher increase in CD4 compared to patients starting cART with prior nucleoside exposure
 - the mean annual CD4 increase within the first 6 months of cART was 64/mm³ higher than the mean annual CD4 slope at 3-6 years after starting cART
- In comparison to periods with virologic suppression
- periods where the VL decreased by > 2 log copies per year had a 123/mm³ per year higher increase in CD4
 - periods where VL was increasing by 0.5-2 log copies per year had a 45/mm³ lower increase in annual CD4 count
 - periods with VL increasing by more than 2 log copies per year had a 140/mm³ per year lower increase in annual CD4 count

CONCLUSIONS

- There were a number of predictors of CD4 slope in patients starting cART after 1 January 1999
- After adjustment for other variables, the rate at which viral load was changing was a strong predictor of the rate of change in CD4 count
- There were some differences between CD4 slope for different cART regimens
- As expected, patients who stopped all ARVs had a rapidly declining CD4 slope
- After adjustment, development of triple class failure was not an independent predictor of CD4 slope

SUMMARY

There are a number of predictors of CD4 slope which will be useful to identify patients with rapidly decreasing CD4 and at the greatest risk of clinical disease progression.

REFERENCES

- Mocroft A et al. Short term clinical disease progression in HIV-1 positive patients taking combination antiretroviral therapy: The EuroSIDA risk score. *AIDS* 2007;21:1867-1875.
- PLATO collaboration. Predictors of trends in CD4 positive T-cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes. *Lancet* 2004;364:51-62.

ACKNOWLEDGEMENTS

The EuroSIDA Study Group

The multicentre study group on EuroSIDA (national coordinators in parentheses).

Argentina: (M Lasso), A Duran, Hospital JM Ramos Mejia, Buenos Aires; **Austria:** (W Vetter) Pulmologisches Zentrum der Stadt Wien, Vienna; **Belarus:** (I Karpenko), A Vassilenko, Belarus State Medical University, Minsk; **VM Mitsura, Gomel State Medical University, Gomel;** O Suetnov, Regional AIDS Centre, Svetlogorsk; **Belgium:** (N Clumeck) S De Wit, B Pöll, Saint-Pierre Hospital, Brussels; R Colebunders, Institute of Tropical Medicine, Antwerp; **Bulgaria:** K Kostov, Infectious Diseases Hospital, Sofia; **Croatia:** J Begovic, University Hospital of Infectious Diseases, Zagreb; **Czech Republic:** (I Machalá) H Ruzyně, Faculty Hospital Bulovka, Prague; D Sedláček, Charles University Hospital, Pilsen; **Denmark:** (J Nielsen) Lundgren, T Benfield, O Kirk, Hvidovre Hospital, Copenhagen; J Gerstoft, T Katzenstein, A B E Hansen, P Skjold, Rigshospitalet, Copenhagen; C Pedersen, Odense University Hospital, Odense; L Ostergaard, Slagelse Hospital, Aarhus; **Estonia:** (K Zimer) West-Tallinn Central Hospital, Tallinn; Jena Soidi, Rakvere Keskhaigla, Rakvere; **France:** (C Katlama) Hôpital de la Pitié-Salpêtrière, Paris; P Varet, Hôpital Necker-Enfants Malades, Paris; P M Girard, Hôpital Saint-Antoine, Paris; JM Linares, Hôpital Edouard Bellet, Lyon; P Vanhems, University Claude Bernard, Lyon; C Pradier, Hôpital de l'Archet, Nice; F Dabis, Unité INSERM, Bordeaux; **Germany:** (J Rockstroh) Universitätsklinik Bonn; R Schmidt, Medizinische Hochschule Hannover; J van Lunzen, O Degen, Universitätsklinikum Hamburg-Eppendorf, Infectious Diseases Unit, Hamburg; H J Stellbrink, IPM Study Center, Hamburg; S Staszewski, JW Goethe University Hospital, Frankfurt; J Bogner, Medizinische Poliklinik, Munich; G Falkenheuer, Universität Köln, Cologne; **Greece:** (K Kionidi) P Gargalianos, O Xylomenos, J Pentos, Athens General Hospital; G Panos, A Filadelfias, E Karabatzi, vti IKA Hospital; I Sambatakou, Ippokratikon General Hospital, Athens; **Hungary:** (D Beregno) Szent László Hospital, Budapest; **Ireland:** (F Mulcahy) St. James's Hospital, Dublin; **Israel:** (I Vardi) D Turner, M Burke, Ichilov Hospital, Tel Aviv; S Pollack, G Hassoun, Rambam Medical Center, Haifa; S Maayan, Hadassah University Hospital, Jerusalem; **Italy:** (A Chiesa) Istituto Superiore di Sanità, Rome; R Esposito, I Mazzeo, C Muscato, Università Modena, Modena; C Anic, Ospedale Riuniti, Bergamo; R Pristera, Ospedale Generale Regionale, Bolzano; F Mazzotta, A Gabutti, Ospedale S Maria Annunziata, Firenze; V Valle, M Lichner, University of Rome la Sapienza, Rome; A Chiariello, E Montesano, M Gargiulo, Previdio Ospedaleiro RD Cotugno, Meridiano Hospital, Napoli; G Antonucci, F Tancini, P Narciso, C Viano, M Zaccarelli, Istituto Nazionale Malattie Infettive Luigi Spallanzani, Rome; A Lazzarin, B Franz, Ospedale San Raffaele, Milan; M Galli, A Ridolfi, Osp. L. Sacco, Milan; A D'Amico, Ospedale, Istituto Di Clinica Malattie Infettive e Tropicale, Milan; **Latvia:** (R Rozentals) P Aldins, Infectology Centre of Latvia, Riga; **Lithuania:** (S Chaplinskis) Lithuanian AIDS Centre, Vilnius; **Luxembourg:** (R Henneff) T Staub, Centre Hospitalier, Luxembourg; **Netherlands:** (P Reiss) Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam; **Norway:** (B Bruun) A Marland, V Ormaasen, Ullevål Hospital, Oslo; **Poland:** (B Kozłowski) J Gasiotowski, Medical University, Wrocław; A Horban, Centrum Diagnostyki i Terapii AIDS, Warszawa; O Prokopenko, A Wiercinska-Drapalo, Medical University, Białystok; A Boron-Kaczmarek, M Pynka, Medical University, Szczecin; M Besnowski, E Mularko, Chorobek Diagnostyki i Terapii AIDS, Chorzów; H Trocha, Medical University, Gdańsk; **Portugal:** (F Antunes) J Valadas, Hospital Santa Maria, Lisbon; E Moutinho, Hospital de Egas Moniz, Lisbon; P Maltez, Hospital Curry Cabral, Lisbon; **Romania:** (D Duvălescu) Spital de Boli Infecțioase și Tropicale Dr. Victor Babeș, București; **Russia:** (A Rakhmanov) Medical Academy Bulletin Hospital, St Petersburg; I Vinogradov, St Petersburg AIDS Centre, St Petersburg; S Buzanova, Novgorod Centre for AIDS, Novgorod; **Serbia:** (D Jevonjić), The Institute for Infectious and Tropical Diseases, Belgrade; **Slovakia:** (M Mokříš) D Stanková, Dier Hospital, Bratislava; **Spain:** (J González-Lahou) V Soriano, J Martín-Carbonero, P Labarga, Hospital Carlos III, Madrid; B Clotet, A Josa, J Canejo, C Tural, Hospital Germans Trias i Pujol, Badalona; JM Gatell, JM Miró, Hospital Clinic i Provincial, Barcelona; P Domingo, M Gutiérrez, O Mateo, MA Sambol, Hospital Sant Pau, Barcelona; **Sweden:** (A Karlsson), Karolinska University Hospital, Stockholm; PO Persson, Karolinska University Hospital, Huddinge; I Frimhagen, Malmö University Hospital, Malmö; **Switzerland:** (S Ledergerber) R Weber, University Hospital, Zurich; P Francini, M Cavasini, Centre Hospitalier Universitaire Vaudois, Lausanne; B Hirschel, E Hoff, Hôpital Central, Université de Genève, Genève; H Furrer, Inselspital Bern, Bern; M Battegay, L Eitzi, University Hospital Basel, Basel; **Ukraine:** (S Kowchenko) B Chertkova, Kiev Centre for AIDS, Kiev; **United Kingdom:** (S Barton) St. Stephen's Clinic, Chelsea and Westminster Hospital, London; AM Johnson, O Mercier, Royal Free and University College London Medical School, London; University College Campus; A Phillips, MA Johnson, A Mocroft, Royal Free and University College Medical School, London (Royal Free Campus); M Murphy, Medical College of Saint Bartholomew's Hospital, London; J Weber, O Scullard, Imperial College School of Medicine at St. Mary's, London; M Fisher, Royal Sussex County Hospital, Brighton; R Brette, Western General Hospital, Edinburgh.

Virology groups: B Clotet (Central Coordinators) plus ad hoc virologists from participating sites in the EuroSIDA Study.

Steering Committee: F Antunes, B Clotet, D Duiculescu, J Gatell, B Gazzard, A Horban, A Karlsson, C Katlama, B Ledergerber (Chair), A D'Amico, Montforto, A Phillips, A Rakhmanova, P Reiss (Vice-Chair), J Rockstroh

Coordinating Centre Staff: Lundgren (overall leader), O Kirk, A Mocroft, W Riss-Walder, A Cozzi-Vegliani, W Benschley, M Elford, A Borck, D Podlekarska, C Holmstrom-Olsen, J Kiser, L Peters, J Bredius

Statement of Funding: Primary support for EuroSIDA is provided by the European Commission BIOMED 1 (CT94-1632), BIOMED 2 (CT97-2713), the 5th Framework (QLK4-2000-00773) and the 6th Framework (LSHM-CT-2006-048632) programs. Current support also includes unrestricted grants by Bristol-Myers Squibb, GlaxoSmithKline, Roche, Glend, Pizer, Merck and Co., Tibotec and Boehringer-Ingelheim. The participation of centres from Switzerland was supported by a grant from the Swiss Federal Office for Education and Science.

Table 1

Characteristics of 1956 patients included in analyses

		N	%
Gender	Male / Female	1363 / 593	69.7 / 30.3
Ethnic Origin	White / Other	1720 / 236	87.9 / 12.1
Exposure	Hom. / Het. / IDU	743 / 404 / 678	38.0 / 20.7 / 34.7
Prior AIDS		75	19.2
cART	Single PI	488	25.0
Regimen	RTV-boosted PI	420	21.5
	NNRTI	960	49.1
	Abacavir	88	4.5
ARV naïve		1408	72.0
	Median		IQR
CD4 at cART		231	120 – 360
VL at cART		4.80	4.03 – 5.32
Nadir CD4		188	90 – 287
Peak VL		4.96	4.38 – 5.44
Date started cART		1/01	1/00 – 6/03
Age		37.4	31.5 – 44.3

Figure 1

Unadjusted CD4 count increase stratified by VL suppression




Figure 2

CD4 slope and cART regimens




Table 2

Multivariate factors associated with CD4 slope

		Annual slope	95% CI	p
Treatment regimen	Off all ARVs	-169.7	-194.6 to -144.8	<0.0001
	1 or 2 ARVs	-20.9	-45.3 to 3.6	0.095
	PI + 2 nucs	-19.7	-32.5 to -7.0	0.0023
	Boosted PI + 2 nucs	0	-	-
	NNRTI + 2 nucs	-14.7	-25.0 to -4.3	0.0053
	Abacavir + 2 nucs	-14.7	-33.8 to 4.5	0.13
	Other ≥ 3 ARVs	-18.4	-36.0 to -0.8	0.040
ARV naïve at cART		21.6	13.3 to 29.8	<0.0001
CD4 at cART	Per doubling	-0.32	-2.47 to 1.84	0.77
VL at cART	Per 1 log higher	1.67	-3.29 to 6.64	0.51
Current VL	Per 1 log higher	7.31	1.14 to 13.48	0.020
Time since cART	< 6 months	63.7	43.9 to 83.5	<0.0001
	6 months- 3 years	37.9	29.1 to 46.8	<0.0001
	3 - 6 years	0	-	-
	> 6 years	-6.7	-24.8 to 11.4	0.47
Change in VL	No change	0	-	-
	≤ 0.5 log decrease	-13.6	-28.0 to 0.8	0.065
	0.5 - 2 log decrease	-1.5	-17.1 to 14.1	0.85
	> 2 log decrease	123.0	101.9 to 144.2	<0.0001
	≤ 0.5 log increase	-22.3	-38.3 to -6.3	0.0063
	0.5 - 2 log increase	-45.1	-58.9 to -31.3	<0.0001
	> 2 log increase	-140.3	-168.7 to -112.0	<0.0001
Develop TCF		-12.6	-27.5 to 2.4	0.10
Date started cART	Per 12 months later	-1.34	-3.91 to 1.24	0.31
Age	Per 10 years older	-4.7	-8.0 to -1.5	0.0040
IDU risk group	Vs other	-5.7	-14.4 to 3.1	0.20